Mirati Therapeutics Inc. clinical trials

Acquired by Bristol-Myers Squibb, Jan 23, 2024 · source ↗

The registry lists 51 studies whose lead sponsor is Mirati Therapeutics Inc.. 3 are recruiting or about to start. Per ClinicalTrials.gov, last updated Oct 13, 2026.

Studies

Recruiting first, then most recently updated. Showing 50 of 51. List all 51 → · All Bristol-Myers Squibb studies →

• Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7RecruitingNCT04613596Phase 2/3

  Sponsor listed in the registry: Mirati Therapeutics Inc. · First submitted before Mirati Therapeutics Inc. became part of Bristol-Myers Squibb

• A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)RecruitingNCT06875310Phase 3

  Sponsor listed in the registry: Mirati Therapeutics Inc. · First submitted after Mirati Therapeutics Inc. became part of Bristol-Myers Squibb

• A Solid Tumor Study for Long Term Treatment of Cancer Patients Who Participated in Adagrasib StudiesRecruitingNCT07415031Phase 2

  Sponsor listed in the registry: Mirati Therapeutics Inc. · First submitted after Mirati Therapeutics Inc. became part of Bristol-Myers Squibb

• Phase 3 Study of Sitravatinib Plus Nivolumab vs Docetaxel in Patients With Advanced Non-Squamous Non-Small Cell Lung CancerTerminatedNCT03906071Phase 3

  Sponsor listed in the registry: Mirati Therapeutics Inc. · First submitted before Mirati Therapeutics Inc. became part of Bristol-Myers Squibb

• Phase 3 Study of MRTX849 With Cetuximab vs Chemotherapy in Patients With Advanced Colorectal Cancer With KRAS G12C Mutation (KRYSTAL-10)Active, not recruitingNCT04793958Phase 3

  Sponsor listed in the registry: Mirati Therapeutics Inc. · First submitted before Mirati Therapeutics Inc. became part of Bristol-Myers Squibb

• A Study to Assess the Pharmacokinetics, Safety and Tolerability of Single-dose Adagrasib (BMS-986503) in Healthy Participants of Japanese DescentCompletedNCT07723118Phase 1

  Sponsor listed in the registry: Mirati Therapeutics Inc. · First submitted after Mirati Therapeutics Inc. became part of Bristol-Myers Squibb

• Trial of Two Adagrasib Dosing Regimens in NSCLC With KRAS G12C Mutation (KRYSTAL 21)Active, not recruitingNCT05853575Phase 2

  Sponsor listed in the registry: Mirati Therapeutics Inc. · First submitted before Mirati Therapeutics Inc. became part of Bristol-Myers Squibb

• Phase 3 Study of MRTX849 (Adagrasib) vs Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C MutationActive, not recruitingNCT04685135Phase 3

  Sponsor listed in the registry: Mirati Therapeutics Inc. · First submitted before Mirati Therapeutics Inc. became part of Bristol-Myers Squibb

• Study of Sitravatinib With or Without Other Anticancer Therapies Receiving Clinical Benefit From Parent StudyCompletedNCT04887870Phase 2/3

  Sponsor listed in the registry: Mirati Therapeutics Inc. · First submitted before Mirati Therapeutics Inc. became part of Bristol-Myers Squibb

• Phase 1/2 Study of MRTX849 in Patients With Cancer Having a KRAS G12C Mutation KRYSTAL-1Active, not recruitingNCT03785249Phase 1/2

  Sponsor listed in the registry: Mirati Therapeutics Inc. · First submitted before Mirati Therapeutics Inc. became part of Bristol-Myers Squibb

• Combination Therapies With Adagrasib in Patients With Advanced NSCLC With KRAS G12C MutationActive, not recruitingNCT05609578Phase 2

  Sponsor listed in the registry: Mirati Therapeutics Inc. · First submitted before Mirati Therapeutics Inc. became part of Bristol-Myers Squibb

• A Phase 1 Study of MRTX0902 in Solid Tumors With Mutations in the KRAS MAPK PathwayTerminatedNCT05578092Phase 1

  Sponsor listed in the registry: Mirati Therapeutics Inc. · First submitted before Mirati Therapeutics Inc. became part of Bristol-Myers Squibb

• Bioequivalence Study Between Adagrasib Reference Tablets and High Drug Load TabletsCompletedNCT06801418Phase 1

  Sponsor listed in the registry: Mirati Therapeutics Inc. · First submitted after Mirati Therapeutics Inc. became part of Bristol-Myers Squibb

• Adagrasib in Combination With Nab-Sirolimus in Patients With Advanced Solid Tumors and Non-Small Cell Lung Cancer With a KRAS G12C Mutation (KRYSTAL -19)TerminatedNCT05840510Phase 1

  Sponsor listed in the registry: Mirati Therapeutics Inc. · First submitted before Mirati Therapeutics Inc. became part of Bristol-Myers Squibb

• Study of MRTX1133 in Patients With Advanced Solid Tumors Harboring a KRAS G12D MutationTerminatedNCT05737706Phase 1

  Sponsor listed in the registry: Mirati Therapeutics Inc. · First submitted before Mirati Therapeutics Inc. became part of Bristol-Myers Squibb

• Adagrasib in Combination With TNO155 in Patients With Cancer (KRYSTAL 2)CompletedNCT04330664Phase 1

  Sponsor listed in the registry: Mirati Therapeutics Inc. · First submitted before Mirati Therapeutics Inc. became part of Bristol-Myers Squibb

• Adagrasib in Combination With Palbociclib in Patients With Advanced Solid Tumors (KRYSTAL-16)CompletedNCT05178888Phase 1

  Sponsor listed in the registry: Mirati Therapeutics Inc. · First submitted before Mirati Therapeutics Inc. became part of Bristol-Myers Squibb

• Adagrasib in Combination With BI 1701963 in Patients With Cancer (KRYSTAL 14)TerminatedNCT04975256Phase 1

  Sponsor listed in the registry: Mirati Therapeutics Inc. · First submitted before Mirati Therapeutics Inc. became part of Bristol-Myers Squibb

• Study of Sitravatinib, Nivolumab and Ipilimumab in Advanced or Metastatic Clear-Cell Renal Cell Carcinoma or Other Solid MalignanciesCompletedNCT04518046Phase 1

  Sponsor listed in the registry: Mirati Therapeutics Inc. · First submitted before Mirati Therapeutics Inc. became part of Bristol-Myers Squibb

• PK Study to Assess Drug-drug Interaction Between Sitravatinib and a P-gp Inducer and an Inhibitor.CompletedNCT05255276Phase 1

  Sponsor listed in the registry: Mirati Therapeutics Inc. · First submitted before Mirati Therapeutics Inc. became part of Bristol-Myers Squibb

• PK Study to Assess Drug-drug Interaction and QTc Between Sitravatinib and a Cocktail of SubstratesCompletedNCT04887194Phase 1

  Sponsor listed in the registry: Mirati Therapeutics Inc. · First submitted before Mirati Therapeutics Inc. became part of Bristol-Myers Squibb

• Phase 2 Study of Glesatinib, Sitravatinib or Mocetinostat in Combination With Nivolumab in Non-Small Cell Lung CancerTerminatedNCT02954991Phase 2

  Sponsor listed in the registry: Mirati Therapeutics Inc. · First submitted before Mirati Therapeutics Inc. became part of Bristol-Myers Squibb

• A PK Study to Assess the Drug-drug Interaction of a BCRP Inhibitor on AdagrasibCompletedNCT05924152Phase 1

  Sponsor listed in the registry: Mirati Therapeutics Inc. · First submitted before Mirati Therapeutics Inc. became part of Bristol-Myers Squibb

• A PK Study to Assess the Drug-drug Interaction of a Strong CYP2C8 Inhibitor on AdagrasibCompletedNCT05868356Phase 1

  Sponsor listed in the registry: Mirati Therapeutics Inc. · First submitted before Mirati Therapeutics Inc. became part of Bristol-Myers Squibb

• A Study to Evaluate the Effect of Mild, Moderate, and Severe Hepatic Impairment on Pharmacokinetics of SitravatinibCompletedNCT04772612Phase 1

  Sponsor listed in the registry: Mirati Therapeutics Inc. · First submitted before Mirati Therapeutics Inc. became part of Bristol-Myers Squibb

• Neoadjuvant Sitravatinib in Combination With Nivolumab in Patients With Clear Cell Renal Cell CarcinomaCompletedNCT03680521Phase 2

  Sponsor listed in the registry: Mirati Therapeutics Inc. · First submitted before Mirati Therapeutics Inc. became part of Bristol-Myers Squibb

• A Phase 2 Study of Sitravatinib in Combination With PD-(L)1 Checkpoint Inhibitor Regimens in Patients With Advanced or Metastatic Urothelial CarcinomaTerminatedNCT03606174Phase 2

  Sponsor listed in the registry: Mirati Therapeutics Inc. · First submitted before Mirati Therapeutics Inc. became part of Bristol-Myers Squibb

• Phase 1/1b Study of MGCD516 in Patients With Advanced CancerCompletedNCT02219711Phase 1

  Sponsor listed in the registry: Mirati Therapeutics Inc. · First submitted before Mirati Therapeutics Inc. became part of Bristol-Myers Squibb

• A Study to Explore the Effect of Acid-reducing AgentsCompletedNCT04935112Phase 1

  Sponsor listed in the registry: Mirati Therapeutics Inc. · First submitted before Mirati Therapeutics Inc. became part of Bristol-Myers Squibb

• A Study to Explore the Effect of Food Before a Single Dose of SitravatinibCompletedNCT04800614Phase 1

  Sponsor listed in the registry: Mirati Therapeutics Inc. · First submitted before Mirati Therapeutics Inc. became part of Bristol-Myers Squibb

• Phase 1/2 Study of Mocetinostat and Durvalumab in Patients With Advanced Solid Tumors and NSCLCTerminatedNCT02805660Phase 1/2

  Sponsor listed in the registry: Mirati Therapeutics Inc. · First submitted before Mirati Therapeutics Inc. became part of Bristol-Myers Squibb

• Phase 2 Study of MGCD265 in Patients With Non-Small Cell Lung Cancer With Activating Genetic Alterations in METCompletedNCT02544633Phase 2

  Sponsor listed in the registry: Mirati Therapeutics Inc. · First submitted before Mirati Therapeutics Inc. became part of Bristol-Myers Squibb

• Safety Study of Oral MGCD265 Administered Without Interruption to Subjects With Advanced MalignanciesCompletedNCT00697632Phase 1

  Sponsor listed in the registry: Mirati Therapeutics Inc. · First submitted before Mirati Therapeutics Inc. became part of Bristol-Myers Squibb

• Safety Study of Mocetinostat in Combination With Azacitidine in Subjects With MDSCompletedNCT02018926Phase 1/2

  Sponsor listed in the registry: Mirati Therapeutics Inc. · First submitted before Mirati Therapeutics Inc. became part of Bristol-Myers Squibb

• Study of Mocetinostat in Patients With Urothelial Carcinoma Having Inactivating Alterations of Specific GenesCompletedNCT02236195Phase 2

  Sponsor listed in the registry: Mirati Therapeutics Inc. · First submitted before Mirati Therapeutics Inc. became part of Bristol-Myers Squibb

• Study of MGCD0103 (MG-0103) in Patients With Relapsed or Refractory Hodgkin's LymphomaTerminatedNCT00358982Phase 2

  Sponsor listed in the registry: Mirati Therapeutics Inc. · First submitted before Mirati Therapeutics Inc. became part of Bristol-Myers Squibb

• MGCD0103 Administered in Combination With Azacitidine (Vidaza®) to Subjects With Relapsed or Refractory Hodgkin or Non-Hodgkin LymphomaTerminatedNCT00543582Phase 2

  Sponsor listed in the registry: Mirati Therapeutics Inc. · First submitted before Mirati Therapeutics Inc. became part of Bristol-Myers Squibb

• A Phase I/II Study of MGCD0103 With Azacitidine in Patients With High-Risk Myelodysplastic Syndrome (MDS) or Acute Myelogenous LeukemiaCompletedNCT00324220Phase 1/2

  Sponsor listed in the registry: Mirati Therapeutics Inc. · First submitted before Mirati Therapeutics Inc. became part of Bristol-Myers Squibb

• A Phase II Study of MGCD0103 (MG-0103) in Patients With Refractory Chronic Lymphocytic LeukemiaCompletedNCT00431873Phase 2

  Sponsor listed in the registry: Mirati Therapeutics Inc. · First submitted before Mirati Therapeutics Inc. became part of Bristol-Myers Squibb

• Study of MGCD0103 Given Three Times Weekly in Patients With Relapsed and Refractory LymphomaCompletedNCT00359086Phase 2

  Sponsor listed in the registry: Mirati Therapeutics Inc. · First submitted before Mirati Therapeutics Inc. became part of Bristol-Myers Squibb

• MGCD0103 in Elderly Patients With Previously Untreated AML/High Risk MDS or Adults With Relapsed/Refractory DiseaseTerminatedNCT00374296Phase 2

  Sponsor listed in the registry: Mirati Therapeutics Inc. · First submitted before Mirati Therapeutics Inc. became part of Bristol-Myers Squibb

• A Phase I/II Study of MGCD0103 (MG-0103) in Combination With GemcitabineCompletedNCT00372437Phase 1/2

  Sponsor listed in the registry: Mirati Therapeutics Inc. · First submitted before Mirati Therapeutics Inc. became part of Bristol-Myers Squibb

• Phase 2 Study of Azacitidine (Vidaza) vs MGCD0103 vs Combination in Elderly Subjects With Newly Diagnosed Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)TerminatedNCT00666497Phase 2

  Sponsor listed in the registry: Mirati Therapeutics Inc. · First submitted before Mirati Therapeutics Inc. became part of Bristol-Myers Squibb

• A Phase I Study of MGCD0103 Given Three-Times Weekly In Patients With Leukemia Or Myelodysplastic SyndromesCompletedNCT00324129Phase 1

  Sponsor listed in the registry: Mirati Therapeutics Inc. · First submitted before Mirati Therapeutics Inc. became part of Bristol-Myers Squibb

• Study to Evaluate Combination Treatment of MGCD0103 and Docetaxel (Taxotere®) for Subjects With Advanced Cancer TumorsTerminatedNCT00511576Phase 1

  Sponsor listed in the registry: Mirati Therapeutics Inc. · First submitted before Mirati Therapeutics Inc. became part of Bristol-Myers Squibb

• A Study of MGCD265 Given With Erlotinib or Docetaxel in Subjects With Advanced Malignancies or Non-Small Cell Lung CancerTerminatedNCT00975767Phase 1

  Sponsor listed in the registry: Mirati Therapeutics Inc. · First submitted before Mirati Therapeutics Inc. became part of Bristol-Myers Squibb

• A Phase I Study of MGCD0103 Given Twice Weekly in Patients With Leukemia or Myelodysplastic SyndromesCompletedNCT00324194Phase 1

  Sponsor listed in the registry: Mirati Therapeutics Inc. · First submitted before Mirati Therapeutics Inc. became part of Bristol-Myers Squibb

• Study of MGCD0103 Given Three-Times Weekly in Patients With Advanced Solid Tumors or Non-Hodgkin's LymphomaCompletedNCT00323934Phase 1

  Sponsor listed in the registry: Mirati Therapeutics Inc. · First submitted before Mirati Therapeutics Inc. became part of Bristol-Myers Squibb

• Safety Study of Two Oral Formulations of MGCD265 Administered in Healthy Subjects in the Fasting StateCompletedNCT01930006Phase 1

  Sponsor listed in the registry: Mirati Therapeutics Inc. · First submitted before Mirati Therapeutics Inc. became part of Bristol-Myers Squibb

• Single Dose Comparative Bioavailability Study Of MGCD265 In Healthy Male And Female VolunteersCompletedNCT02117245

  Sponsor listed in the registry: Mirati Therapeutics Inc. · First submitted before Mirati Therapeutics Inc. became part of Bristol-Myers Squibb